Tethys Bioscience
Operating Status: Closed
Tethys Bioscience develops biomarker-based blood tests to predict imminent disease risks and cardiometabolic conditions.
Founded
2002Tethys Bioscience develops biomarker-based blood tests to predict imminent disease risks and cardiometabolic conditions.
Tethys Bioscience, founded with the mission to revolutionize disease prediction, focuses on developing and commercializing biomarker-based blood tests. The company's core vision is to enable early detection and prevention of serious health conditions, thereby improving patient outcomes. Tethys offers products that predict imminent risks for diseases such as diabetes, first-time heart attacks, and osteoporotic fractures, targeting a market that prioritizes proactive healthcare and personalized medicine.
Notable figures associated with Tethys Bioscience include leading experts in the fields of biotechnology and healthcare innovation. The company has attracted significant investment from prominent venture capital firms, underscoring confidence in its innovative approach. Key achievements include the successful development and commercialization of predictive blood tests that have had a substantial impact on early disease detection and prevention strategies. Tethys Bioscience continues to influence the healthcare industry by providing tools that help mitigate the risks of severe cardiometabolic diseases.
Companies similar to Tethys Bioscience include Liquid Biotech, Gryphon Bio, Metfora and Glycotest.
Tethys Bioscience was founded in 2002.
Tethys Bioscience's headquarters is located in Emeryville, CA, US.
Tethys Bioscience's most recent funding round was for $12M (USD) in January 2012.
As of Jan 1, 2012, Tethys Bioscience has disclosed funding of $75.4M (USD). Undisclosed round amounts are excluded.
Glycotest
glycotest.com
